COMP <GO>
RSKD vs NUTX // FREE CASH FLOW YIELD
Riskified Ltd. (Class A) (NYSE) VS. Nutex Health Inc. (NASDAQ) • 15-METRIC TALLY: RSKD 3
— NUTX 7
▲ FREE CASH FLOW YIELD LEADER: NUTX
LAST: $8.99 (-0.55%) • MKT CAP: $1.22B
fcf-yield
2.71%
LAST: $210.10 (-1.19%) • MKT CAP: $1.44B
fcf-yield
17.07%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RSKD VS. NUTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RSKD | NUTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.70% | 50.80% | +0.90 | RSKD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.30% | 85.00% | -105.30 | NUTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 4.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 2.71% | 17.07% | -14.36 | NUTX | /fcf-yield <GO> |
| Operating Margin | -9.90% | 31.50% | -41.40 | NUTX | /operating-margins <GO> |
| Net Profit Margin | -8.00% | 8.10% | -16.10 | NUTX | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 82.40% | -77.20 | NUTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.12 | 3.75 | +2.37 | RSKD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | NUTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.6 | 46.7 | +8.89 | RSKD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.22B | $1.44B | -$216.4M | NUTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RSKD REV | NUTX REV | RSKD GROSS % | NUTX GROSS % | RSKD FCF | NUTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $344.6M | $875.3M | 51.7% | 50.8% | $33.1M | $245.6M |
| FY 2024 | $327.5M | $479.9M | 52.2% | 40.9% | $39.1M | $20.8M |
| FY 2023 | $297.6M | $247.6M | — | — | $7.3M | $1.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RSKD // BETA —
NUTX // BETA —